MORF Company Profile and Key Details

Q: Who are the executives of MORF?

Dr. Marc Schegerin M.B.A., M.D.Chief Financial Officer & Chief Operating OfficerMr. William D. DeVaul Esq.Gen. Counsel & Sec.Dr. Praveen P. Tipirneni M.D.Chief Executive Officer, MD & DirectorDr. Blaise Lippa Ph.D.Chief Scientific OfficerDr. Bruce N. Rogers Ph.D.PresDr. Timothy A. Springer Ph.D.Founder, Independent Director & Member of Scientific Advisory BoardMr. Aaron PeltaSenior Vice President of Bus. & Corporation Devel.Mr. Robert E. Farrell Jr., CPA, CPASenior Vice President of Fin. & Chief Accounting OfficerMr. Robert E. Farrell Jr., C.P.A., CPASenior Vice President of Fin. & Chief Accounting OfficerMs. Joanne GibbonsSenior Vice President of Regulatory Affairs

NASDAQ : MORF

Morphic Holding

$56.99

0.02+0.04%

At Close 4:00 PM

Not Actively Trading

55.11

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Morphic Holding, Inc. (MORF) stock surged +0.04%, trading at $56.99 on NASDAQ, up from the previous close of $56.97. The stock opened at $56.97, fluctuating between $56.97 and $57.00 in the recent session.

Stock Snapshot

56.97

Prev. Close

2.86B

Market Cap

56.97

Day Low

-14.879895561357703

P/E Ratio

-3.83

EPS (TTM)

-2.28

Cash Flow per Share

56.97

Open

50.22M

Number of Shares

Day High

67.5%

Free Float in %

14.01

Book Value

1.74M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Aug 15, 2024	56.97	56.99	56.97	56.99	1.79M
Aug 14, 2024	56.98	56.98	56.97	56.97	1.13M
Aug 13, 2024	56.95	56.98	56.95	56.97	1.46M
Aug 12, 2024	56.92	56.95	56.92	56.94	998.94K
Aug 09, 2024	56.91	56.91	56.89	56.90	1.33M
Aug 08, 2024	56.88	56.92	56.88	56.88	1.32M
Aug 07, 2024	56.86	56.90	56.85	56.89	1.96M
Aug 06, 2024	56.86	56.90	56.84	56.87	1.46M
Aug 05, 2024	56.84	56.90	56.76	56.82	4.1M
Aug 02, 2024	56.83	56.92	56.81	56.84	3.44M
Aug 01, 2024	56.82	56.85	56.81	56.82	2.78M
Jul 31, 2024	56.74	56.74	56.66	56.66	1.94M
Jul 30, 2024	56.62	56.78	56.56	56.77	1.83M
Jul 29, 2024	56.60	56.62	56.53	56.60	1.24M
Jul 26, 2024	56.61	56.64	56.52	56.55	1.41M
Jul 25, 2024	56.53	56.61	56.50	56.61	1.48M
Jul 24, 2024	56.52	56.58	56.43	56.55	1.51M
Jul 23, 2024	56.56	56.60	56.46	56.53	1.28M
Jul 22, 2024	56.59	56.59	56.46	56.59	1.49M
Jul 19, 2024	56.40	56.55	56.35	56.52	1.91M

Contact Details

Waltham, MA 02451

United States

https://www.morphictx.com 781 996 0955

About Company

Morphic Holding, Inc. is a biopharmaceutical company dedicated to the discovery and advancement of oral, small-molecule integrin-based therapies. These treatments are designed to address a broad spectrum of conditions, including autoimmune, cardiovascular, and metabolic diseases, as well as various forms of fibrosis and cancer. The company's principal therapeutic candidates include MORF-057, an a4ß7-specific integrin inhibitor targeting inflammation, currently undergoing Phase 1 clinical trials for inflammatory bowel disease and in preclinical development for idiopathic pulmonary fibrosis and other fibrotic ailments. Additionally, Morphic is progressing avß6 for fibrotic disorders and avß8 for solid tumor applications, alongside a pipeline of other innovative products. Morphic has established strategic collaborations, including a research partnership with Engitix Ltd concerning integrin technology for fibrostenotic IBD, an agreement with Schrödinger, LLC focused on integrin targets, and a licensing arrangement with Children's Medical Center Corporation for the global development and commercialization of products for human and veterinary therapeutic or diagnostic uses. Further collaborative efforts involve AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. for the discovery and development of integrin-based therapeutics. Established in 2014, Morphic Holding, Inc. operates from its headquarters in Waltham, Massachusetts.

Stock Peers

ARGX

36.15+4.24%

argenx SE$888.65 REGN

-3.29-0.53%

Regeneron Pharmaceuticals, Inc.$620.14 UTHR

-6.51-1.18%

United Therapeutics Corporation$543.39 MDGL

4.03+0.79%

Madrigal Pharmaceuticals, Inc.$513.79 VRTX

4.98+1.05%

Vertex Pharmaceuticals Incorporated$480.18 KRYS

12.3+3.54%

Krystal Biotech, Inc.$359.93 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

18.92+6.12%

Praxis Precision Medicines, Inc.$327.86 LGND

11.01+3.86%

Ligand Pharmaceuticals Incorporated$295.92 ALNY

-0.89-0.30%

Alnylam Pharmaceuticals, Inc.$293.17

Company Overview

Morphic Holding, Inc. (NASDAQ:MORF) closed at $56.99 USD, gaining $0.02 (0.04%) from the previous close of $56.97. The stock is currently trading near its 52-week high $19.34 and $57.00. With a market capitalization of about $2.86 billion, Morphic Holding, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.49). Key stats such as the average daily volume over the past year has been around 2.45 million shares, in line with its 52-week average. Headquartered in Waltham, MA, Morphic Holding, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Praveen P. Tipirneni, the company employs approximately 128 people and listed since June 27, 2019. Morphic Holding, Inc. is a biopharmaceutical company dedicated to the discovery and advancement of oral, small-molecule integrin-based therapies.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.4%, SMA50 25.27%, SMA200 68.88%). The stock’s 14-day RSI is 83.48 (overbought), while the ATR of 0.52 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.02% below its high and over 194.6% above its low.

Valuation Metrics

Morphic Holding, Inc. trades at a P/E ratio of -15.87, slightly below the S&P 500 average, with a price-to-sales ratio of 5493.87 and a price-to-book ratio of 3.47 trading at moderately above to book value. The P/FCF stands at -25.21, also below market averages.

Dividend & Fair Value

Morphic Holding, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.07. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Morphic Holding, Inc. generated EPS of -$3.60 over the past year. Five-year average earnings growth is -35.64%. The latest quarter delivered EPS of -$1.15. The next quarter is forecast at -$1.07. Next year's EPS is expected at -$10.49. Morphic Holding, Inc. earnings surprise history is a mixed track record. The quarter that ended July 25, 2024, missed forecasts by 19.79%. The prior quarter beat by -5.21%. Over the last six quarters, Apple has recorded several small beats. These include 2.22% in August 03, 2023.

Shareholding & Insider Activity

Morphic Holding, Inc. has 50.22 million shares outstanding. The public float is 33.90 million shares, elevated short interest at 7.55% of float. This equals 1.90 million shares. The short ratio is 0.37 days. Institutional investors hold 109.84% of the float. Insiders own 17.13%. SPRINGER TIMOTHY A holds 2.77 million shares, Omega Fund V, L.P. has 2.07 million shares and Rogers Bruce has 149.88 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Morphic Holding generated $521.00K in revenue, or $0.01 per share. Gross margin was -109.40%, operating margin -34296.74%, and net profit margin -29192.90%. Returns are negative, with ROA at -21.05% and ROE at -21.82%.
On valuation metrics, Morphic Holding trades at a P/E of -15.87, P/S of 5493.87 and P/B of 3.47. The current ratio is 28.94 and quick ratio is 28.94. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -2575.41 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -47.91.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Morphic Holding posted revenue of $521.00K, down slightly from $70.81M in the prior quarter. Gross profit was - $570.00K (margin -109.40%). Operating income was - $178.69M (margin -34296.7%). Net income was- $152.10M (EPS - $3.59).
The company ended the quarter with $704.35M in cash and short-term investments, a total debt of $2.34M, and net debt of - $56.23M. Total assets were $722.51M, with equity of $697.02M. Financials further reflected weakness, with operating cash flow of - $112.31M, free cash flow of - $113.55M, and capital expenditures of - $1.24M.

Price Forecast & Outlook

Our AI price prediction model suggests that Morphic Holding, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.21%, with price expected at $63.95 by August 29, 2024, within a range of $55.90 to $72.46 3-Month Outlook: Projected rise of 16.46%, reaching $66.37 by November 13, 2024, with a range of $64.53 to $69.86. 1-Year Outlook: Projected loss of -13.6%, with price at $49.24 by August 15, 2025, within a range of $43.94 to $54.00.

Key Takeaways

Morphic Holding, Inc. (NASDAQ:MORF) shares are up 97.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Morphic Holding, Inc. trading at a premium to the broader market with a P/E of -15.87. Analyst sentiment is cautious, with the majority of ratings in Sector Perform territory and a mean price target of $60.44, suggesting 6.05% upside. Our AI forecast model points to short-term strength (12.21% over two weeks), a medium-term rise (16.46% over three months), and a longer-term loss (-13.6% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Morphic Holding, Inc. (MORF) stock price?

Morphic Holding, Inc. (NASDAQ: MORF) stock price is $56.99 in the last trading session. During the trading session, MORF stock reached the peak price of $57.00 while $56.97 was the lowest point it dropped to. The percentage change in MORF stock occurred in the recent session was 0.04% while the dollar amount for the price change in MORF stock was $0.02.

MORF's industry and sector of operation?

The NASDAQ listed MORF is part of Biotechnology industry that operates in the broader Healthcare sector. Morphic Holding, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MORF?

Dr. Marc Schegerin M.B.A., M.D.
Chief Financial Officer & Chief Operating Officer
Mr. William D. DeVaul Esq.
Gen. Counsel & Sec.
Dr. Praveen P. Tipirneni M.D.
Chief Executive Officer, MD & Director
Dr. Blaise Lippa Ph.D.
Chief Scientific Officer
Dr. Bruce N. Rogers Ph.D.
Pres
Dr. Timothy A. Springer Ph.D.
Founder, Independent Director & Member of Scientific Advisory Board
Mr. Aaron Pelta
Senior Vice President of Bus. & Corporation Devel.
Mr. Robert E. Farrell Jr., CPA, CPA
Senior Vice President of Fin. & Chief Accounting Officer
Mr. Robert E. Farrell Jr., C.P.A., CPA
Senior Vice President of Fin. & Chief Accounting Officer
Ms. Joanne Gibbons
Senior Vice President of Regulatory Affairs

How MORF did perform over past 52-week?

MORF's closing price is 194.6% higher than its 52-week low of $19.35 where as its distance from 52-week high of $57.00 is -0.02%.

How many employees does MORF have?

Number of MORF employees currently stands at 128.

Link for MORF official website?

Official Website of MORF is: https://www.morphictx.com

How do I contact MORF?

MORF could be contacted at phone 781 996 0955 and can also be accessed through its website. MORF operates from 35 Gatehouse Drive, A2, Waltham, MA 02451, United States.

How many shares of MORF are traded daily?

MORF stock volume for the day was 1.74M shares. The average number of MORF shares traded daily for last 3 months was 2.45M.

What is the market cap of MORF currently?

The market value of MORF currently stands at $2.86B with its latest stock price at $56.99 and 50.22M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	128
Beta	1.49
Sales or Revenue	$521.00K
5Y Sales Change%	-0.916%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MORF Company Profile and Key Details

Morphic Holding

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics